FDA stands by safety of approved drugs

	Tweet

The U.S. Food and Drug Administration said on Friday that Senate testimony by a veteran FDA researcher regarding safety risks for five drugs does not reflect the views of the agency.

Dr. David Graham, speaking at a Senate hearing Thursday, singled out Abbott Laboratories Inc.’s weight-loss drug Meridia, AstraZeneca Plc’s cholesterol fighter Crestor, Pfizer Inc.’s arthritis treatment Bextra, Roche’s acne drug Accutane and GlaxoSmithKline’s asthma drug Serevent.

"The five specific drugs that Dr. Graham identified in his oral testimony are currently approved as safe and effective for use in the United States,” Dr. Steven Galson, acting director for the FDA’s Center for Drug Evaluation and Research, said in a statement published on the FDA Web site.

“FDA takes all allegations of safety risks seriously and will continue its longstanding practice of assessing the safety of all drugs using only sound science and peer-reviewed analysis and literature,” Galson added. 

RELATED STORIES:
Topical drug best for smallpox vaccine side effects   Study: Brand drug prices outpace inflation   U.S. hopes to cope with flu shot shortage   Drug makers, online sellers meet in Manitoba   Xenical linked to kidney stone formation in rats   Drug use in strict Singapore waning, gov’t says   Statins may cut pneumonia deaths: study   FDA Says None of Chiron Influenza Vaccine Safe for Use   Eli Lilly played down risks of top drug   Don’t compromise safety, says drug import report   New pill may help recovering alcoholics stay sober   UK animal protests scare off drug firm suppliers

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]